Sevuparin

Our lead candidate – Designed to restore blood flow.

Read more about our research

About sevuparin

Sevuparin is Modus Therapeutics’ candidate drug in clinical development, originating from research at Karolinska Institutet, Sweden and Uppsala University, Uppsala.

Designed for a purpose

Sevuparin has been designed, through a chemical depolymerization of heparin, with the aim to optimize its anti-adhesive and anti-inflammatory effects, while increasing the therapeutic window by removal of the anti-thrombin binding sites. Preclinical studies with sevuparin have shown that the broad anti-adhesive and thus anti-inflammatory effects are retained from heparin, however with a substantially reduced effect on anti-coagulation. Thus the primary pharmacology of sevuparin is anti-adhesive and anti-inflammatory and not anti-coagulant.

Potential use

The first potential treatment use for sevuparin could be in treatment of the painful crises in acute painful crisis in SCD patients. Currently, a clinical phase II trial is ongoing with sevuparin to treat acute painful crisis in hospitalized Sickle Cell Disease patients.

Proprietary compound

As a New Chemical Entity (NCE), patent applications with compositional matter for sevuparin, use in several clinical indications as well as manufacturing process have been filed and they are currently in national phase. Modus Therapeutics holds global rights to all patent applications. In addition, sevuparin has also obtained Orphan Drug Designation (ODD) for Sickle Cell Disease with FDA and EMA. The ODDs provide regulatory assistance during drug development, reduction in user-fees and up to ten years of market exclusivity.

Learn more about SCD

Sevuparin has been designed to reach optimal anti-adhesive properties.

Mats WahlgrenInventor

Professor at Karolinska Institutet

How sevuparin works

Sevuparin has the ability to restore blood flow during microvascular obstructions by exerting its anti-adhesive effects via several key adhesion receptors (broad mechanism of action). This has been shown at molecular and cellular levels as well as in animal models.

As an anti-adhesive therapy, sevuparin, has the potential to be beneficial in several clinical indications, where blood flow is restricted. One such indication is Sickle Cell Disease (for more information see illustration below).

Unique Features of sevuparin

Sevuparin belongs to the well-known chemical class of heparinoids, and has been designed to have anti-adhesion/anti-inflammatory effects as its primary pharmacology. Sevuparin is manufactured in a controlled, chemical depolymerisation process, proprietary to Modus Therapeutics. Sevuparin has the potential to be administered both intravenously and subcutaneously.

Sevuparin’s potential to restore blood flow is unique and holds promise in several diseases where blockage in the blood microvessels is an underlying problem. We are particularly excited about the Ease program in SCD.

Christina Herder

CEO

News

LaBiotech interview with Modus

Learn more about our study in the Middle East.

Innovative Bahraini Deal Inked For Sickle Cell Therapy

Modus Therapeutics AB announced Feb. 16, the Middle East University has shouldered some of the risk of developing sevuparin.

Modus Therapeutics planerar en studie med en ny behandling mot blodsjukdomen sicklecellanemi

Modus Therapeutics har ingått ett samarbetsavtal med Ergomed för den fas II-utvecklingen av heparinderivatet sevuparin i patienter med blodsjukdomen sicklecellanemi, SCD.